A cell line (Bl) was established from the bone marrow of a patient with a relapse of acute leukemia characterized by a 4;ll chromosomal translocation and biphenotypic features of early B and myeloid lineages. Analysis of the growth requirements of this cell line showed density-dependent growth and secretion of an autostimulatory growth factor, suggesting an autocrine mechanism. Several lines of evidence implicate the participation of interleukin-l (IL-l) in the autocrine growth regulation of B1 cells. These cells constitutively express the messenger RNA (mRNA) for IL-1 and IL-1 receptor and secrete IL-1; recombinant IL-1 stimulated the growth of colonies when cells were seeded at low density, and anti-IL-1 antibodies inhibited the growth of colonies CUTE LEUKEMIA is a malignant process character-A ized by unrestricted growth and maturational arrest of lymphoid or myeloid precursor cells. Because the proliferation of normal cells of hematopoietic origin is controlled by growth factors, it has been suggested that leukemias may arise by dysregulation of these pathways.' Leukemic cells may become independent of exogenous growth factors that normally control proliferation and differentiation by acquiring the ability to synthesize and respond to endogenous growth factors. Autocrine growth, whereby a cell constitutively produces its own growth factor, has been demonstrated with various malignancies: including Several studies have shown that interleukin-3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) are involved in autocrine pathways regulating the proliferation of murine leukemic cells.6-* However, the role of hematopoietic factors on the growth of human leukemic cells is still not clear. Blast cells derived from leukemic patients are often dependent on exogenous growth factors for their proliferation in vitro'; their growth in vivo may also be dependent on such hematopoietic growth factors. Previous studies have shown that autocrine circuits were not involved in the proliferation of acute lymphoblastic leukemia (ALL) cells in vitro, but that IL-1 and GM-CSF were involved in the proliferation of acute myelogenous leukemia (AML) c e l l~. 9 -~~'~ Conversely, some cytokines may inhibit the growth of hematopoietic and leukemic cells. For example, tumor necrosis factor-a (TNF-a) was reported to inhibit the growth of AML cells." Specific chromosomal translocations are often associated with malignant transformation of hematopoietic cells arrested at a particular stage of differentiation.'* The chromosome translocation t (4;ll) (q21;q23) has been found primarily in acute leukemia of early infancy, where it has been associated with a poor response to conventional Analysis of leukemic cells with this translocation showed phenotypic markers of B-cell precursors combined with features of myeloid or T The expression of markers of both early lymphoid and myeloid cells on leukemic cells with a t (4;ll) translocation suggests that these cells originate from an uncommitted hematopoietic precursor cell with dual lineage capabilities. It has been suggested that uncommitted hematopoietic progenitors may express multiple receptors for factors that regulate growth and maturation in a lineage-restricted fashion." In the present study we report constitutive expression of multiple receptors for growth factors on a cell line with a t (4;ll) chromosomal translocation and suggest a role for these lymphokine receptors in the proliferation and differentiation of these leukemic cells.
A cell line (Bl) was established from the bone marrow of a patient with a relapse of acute leukemia characterized by a 4;ll chromosomal translocation and biphenotypic features of early B and myeloid lineages. Analysis of the growth requirements of this cell line showed density-dependent growth and secretion of an autostimulatory growth factor, suggesting an autocrine mechanism. Several lines of evidence implicate the participation of interleukin-l (IL-l) in the autocrine growth regulation of B1 cells. These cells constitutively express the messenger RNA (mRNA) for IL-1 and IL-1 receptor and secrete IL-1; recombinant IL-1 stimulated the growth of colonies when cells were seeded at low density, and anti-IL-1 antibodies inhibited the growth of colonies CUTE LEUKEMIA is a malignant process character-A ized by unrestricted growth and maturational arrest of lymphoid or myeloid precursor cells. Because the proliferation of normal cells of hematopoietic origin is controlled by growth factors, it has been suggested that leukemias may arise by dysregulation of these pathways.' Leukemic cells may become independent of exogenous growth factors that normally control proliferation and differentiation by acquiring the ability to synthesize and respond to endogenous growth factors. Autocrine growth, whereby a cell constitutively produces its own growth factor, has been demonstrated with various malignancies: including Several studies have shown that interleukin-3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) are involved in autocrine pathways regulating the proliferation of murine leukemic cells.6-* However, the role of hematopoietic factors on the growth of human leukemic cells is still not clear. Blast cells derived from leukemic patients are often dependent on exogenous growth factors for their proliferation in vitro'; their growth in vivo may also be dependent on such hematopoietic growth factors. Previous studies have shown that autocrine circuits were not involved in the proliferation of acute lymphoblastic leukemia (ALL) cells in vitro, but that IL-1 and GM-CSF were with cells seeded at higher density. B1 cells do not express detectable levels of mRNA for any of the other cytokines tested, and other cytokines failed t o support the growth of B1 cells at low density. In addition, B1 cells express multiple cytokine receptor genes, including the receptors for IL-6, IL-7, tumor necrosisfactor and y-interferon. Addition of the respective cytokines t o the B1 cells resulted in inhibition of the growth of leukemic cells in vitro. The multiplicity of growthinhibitory cytokine receptors on this leukemic cell line might be due t o its biphenotypic lineage and may suggest new therapeutic possibilities in controlling leukemic cell proliferation.
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involved in the proliferation of acute myelogenous leukemia (AML) c e l l~. 9 -~~'~ Conversely, some cytokines may inhibit the growth of hematopoietic and leukemic cells. For example, tumor necrosis factor-a (TNF-a) was reported to inhibit the growth of AML cells."
Specific chromosomal translocations are often associated with malignant transformation of hematopoietic cells arrested at a particular stage of differentiation.'* The chromosome translocation t (4;ll) (q21;q23) has been found primarily in acute leukemia of early infancy, where it has been associated with a poor response to conventional Analysis of leukemic cells with this translocation showed phenotypic markers of B-cell precursors combined with features of myeloid or T The expression of markers of both early lymphoid and myeloid cells on leukemic cells with a t (4;ll) translocation suggests that these cells originate from an uncommitted hematopoietic precursor cell with dual lineage capabilities. It has been suggested that uncommitted hematopoietic progenitors may express multiple receptors for factors that regulate growth and maturation in a lineage-restricted fashion." In the present study we report constitutive expression of multiple receptors for growth factors on a cell line with a t (4;ll) chromosomal translocation and suggest a role for these lymphokine receptors in the proliferation and differentiation of these leukemic cells.
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The B1 cells were cloned in semisolid methyl cellulose (0.9% Methocel; Dow Chemical Co, Midland, MI). The cloned cell line maintained the immunologic markers of the original leukemic blasts derived from the bone marrow at the time of relapse.
B1 colony growth assays were performed in semisolid medium. B1 cells, at the indicated density, were plated in 35-mm Lux suspension dishes (Nunc, Inc, Naperville, IL) in aMEM medium containing 10% FBS (Flow-Select Fetal Bovine Serum) in methyl cellulose (0.9%, in Methocel, Dow Chemical Co). Duplicate culture dishes were incubated at 37°C with 5% CO, in air in a humidified atmosphere. Colonies ( 2 2 0 cells) were counted after 8 days using an inverted microscope.
Quantitation of messenger RNA ( "A) of cytokines and cytokine receptors by thepolymerase chain reaction (PCR). The quantitation of specific mRNA species by PCR was performed using synthetic DNA as an internal standard, as previously described." The technique involves co-amplification of a target cDNA (produced from the corresponding mRNA by reverse transcription) and of the internal standard. The target cDNA and the internal standard use the same primer sequences but yield PCR products of different sizes that can be separated by gel electrophoresis. In the exponential phase of the amplification, the amount of target cDNA can be quantified by comparison with the amplification of varied amounts of internal standard. The internal standard synthesized contains the primer sequences for multiple cytokines and cytokine receptor genes constructed by the technique of oligonucleotide overlap extension, as previously described.18 The specific 5' and 3' primers used were designed based on published cytokine and cytokine receptor cDNAs sequences'YJ3 and are listed in Table 1 . Specific primers were used for reverse transcription. These primers corresponded to mRNA sequences downstream from each 3' PCR primer. The use of specific primers (complementary to the corresponding mRNAs rather than oligo[dT]) for the reverse transcription reaction added additional specificity to the PCR and ensured that only the target mRNA was amplified.
Total cellular RNA was prepared according to the methods of Chomczynski and S a~c h i .~~ RNA concentrations were measured spectrophotometricaly (Beckman Instruments DU-40; Fullerton, CA). The integrity of the RNA was confirmed by electrophoresis under denaturing conditions on a 1% agarose gel.
Colony growth assays.
cDNA was prepared by reverse transcription at 37°C for 60 minutes in a 20-kL reaction mixture containing 2 kg of total cellular RNA, 1 mmoliL dithiothreitol, 0.5 mmol/L dNTP, 0.1 kmol of a specific oligonucleotide primer, and 100 units of recombinant Molony murine leukemia virus (MMLV) reverse transcriptase (Bethesda Research Laboratories, Rockville, MD). Internal standard DNA (0.1 to 3.0 pg) and cDNA (produced from 100 to 300 ng total cell RNA) were amplified together with 1 unit of Thermus aquaticrcs DNA polymerase (Taq polymerase; PerkinElmeriCetus, Montreal, Canada) and 50 mmoVL dNTP, 0.1 mmol/L each of the 5' and 3' primers (1 X lo6 cpm of y3*P-end-labeled primer was added where indicated) in a total volume of 50 kL. The mixture was overlaid with mineral oil and then amplified using a thermal cycler (Ericomp, San Diego, CA) over a number of cycles (indicated in text), denaturing at 95°C for 30 seconds, primer annealing at 54°C for 30 seconds, and extending at 72°C for 1 minute. Oligonucleotides were end-labeled with [y-"P] ATP and separated from unincorporated nucleotide with a Sephadex G-50 column. Ten microliters of PCR product were electrophoresed using 8% polyacrylamide gels in Tris borateiEDTA buffer. Gels were stained with ethidium bromide and photographed. When radiolabeled oligonucleotides were incorporated into the amplified product, the gels were dried and autoradiographed at -70°C. For quantitative analysis the appropriate bands were excised from the gel and radioactivity determined by scintillation counting. The amount of radioactivity recovered from the excised internal standard gel bands was plotted against the corresponding internal standard DNA concentration and the amount of cDNA present in each sample calculated from the standard curve.
Cytokines, antibodies, and enzyme-linked immunosorbent assay (ELZSA). Human recombinant IL-la (rhuIL-la; specific activity 3 x 10' Uimg) was a gift from Hoffmann-La Roche (Nutley, NJ); rhuIL-2 (3 x lo6 Uimg protein) was purchased from Genzyme Co (Boston, MA); rhuIL-3 (6 x lo6 Uimg), rhuIL-4 (1.2 x lo4 Uimg), rhuIL-5 (1.2 x lo3 Uimg), rhuIL-6 (4 x lO'Uimg), rhuIL-7 (3 x 10' Uimg), rhuGM-CSF (10.6 x lo6 Uimg), and recombinant human granulocyte-CSF (rhuG-CSF; 3 X lo4 UlmL) were a gift from Genetics Institute (Cambridge, MA); rhuTNF-a (5.6 x lo' UimL) was a gift from Genentech, Inc (South San Francisco, CA); purified rabbit antihuman IL-1p antibody was purchased from Genzyme; Sequences of 5' and 3' primers for amplification of cytokines and cytokine receptor cDNAs were chosen from published cDNA s e q~e n c e s . '~-~~ The primers were designed to give a melting temperature greater than 58"C, PCR products for the various cytokine cDNAs of 310 to 370 bp, and an internal standard PCR product of 230 to 260 bp as listed in the table above. The PCR reaction was performed on cDNA obtained using specific reverse transcription primers downstream to the 3' primer sequences listed above. 
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CD33
CD14 HLA-DR Fig 2 . Flow cytometric analysis of B1 cell line. Cells (5 x 10') were incubated with rhodamine-conjugated B4-lgG (CD19) and with either FITC-conjugated My9 IgG (CD33) or My4 IgG (CD14) in the left and center panels, respectively. The gates were set with control rhodamine-lgGl and FITC-lgG2a. Ninety-nine percent of the cells expressed the CD19 antigen, while 12% of these cells also expressed the CD33 antigen; no cells were found t o express the CD14 antigen. Cells were also stained with rhodamine-T3-lgG (CD3) and FITC-I3 IgG (HLA-DR), as shown in the right panel. Ninety-one percent of the cells expressed HLA-DR while less than 2% reacted with T3 monoclonal antibody (Mob); 7% cells were found in the double-negative quadrangle. Thus, these celk bear the pre-B ALL marker CD19 and a subset of cells express the CD33 monocytic marker; the HLA-DR marker is present on leukemic cells of both lineages.
activity resided in the molecular weight range between 10 and 30 Kd.
These data suggest the participation of autocrine factor(s) in the growth of B1 cells. To identify and characterize these growth factors we studied the repertoire of cytokines and their receptors expressed in the B1 leukemic cells.
Expression of cytokine and cytokine receptor genes in the Bl leukemic cell line. A nonquantitative PCR was used as a preliminary screen to determine the presence of cytokine and cytokine receptor mRNAs in the B1 cells (Fig 4) . An internal standard DNA was used as a positive control in each reaction (refer to Materials and Methods) (lower bands of -250 bp in Fig 4) . The results of this analysis showed the presence of mRNAs for both IL-1p and IL-IR in B1 leukemic cells (350-bp band in Fig 4A) and raised the possibility that IL-1 may participate in the autocrine growth observed in B1 cells.
The mRNAs for the receptors for IL-6, IL-7, yIFN, and TNF were expressed in B1 cells but no mRNA was detected for the corresponding cytokines (Fig 4B) . GM-CSF or their corresponding receptors was detectable in B1 cells (data not shown). The PCR products of the preliminary screening were detected by ethidium bromide staining under amplification conditions that ensure detection of mRNA species exceeding greater than 0.002% of total cell RNA.
To determine whether the expression of IL-lp by B1 cells is associated with the production of IL-lp protein, we have measured the secretion of IL-lp by B1 cultures using specific ELISA. B1 cells (4 x lo6 cells/mL) were found to secrete 24.5 pg/mL IL-1p into the medium over 24 hours of incubation. This value is a minimal estimate for IL-lfi by B1 cells because some of the cytokine secreted by these cells may be bound and internalized by the corresponding receptors present on B1 cells.
The role of IL-1 in autocrine growth of the Bl leukemic cell line. To determine whether IL-1 was involved in autocrine growth control of B1 cells, we first analyzed the effect of IL-la on the growth of B1 cells at various cell densities ( Fig  5) . IL-la and IL-1p can be used interchangibly for this purpose since both bind to the same receptor." IL-1 markedly stimulated B1 cell growth at low cell densities (15-fold stimulation at 2.5 X lo3 cells/mL) while its effect progressively decreased at higher cell densities and was completely ineffective at the highest cell density tested (5 X le cells/mL). These results are consistent with a role for IL-1 in the positive autocrine growth control observed in B1 cells. In addition, we tested the effect of anti-IL-lp antibody on the growth of B1 cells (Fig 6) . Addition of rabbit anti-IL-lp antibodies significantly inhibited (47%) the growth of B1 cells relative to unstimulated controls. Normal rabbit serum did not affect the growth of B1 cells (data not shown). Taken together, these data suggest that IL-1 participates in an autocrine cycle promoting the growth of B1 cells.
Inhibition of Bl growth by IL-6, IL-7, TNFq and yZFN.
Because B1 cells express the genes of four other cytokine receptors, IL-6, IL-7, TNF, and yIFN, we analyzed the effect of exogenous cytokines on B1 cell growth. Figure 6 illustrates that IL-6, IL-7, TNF, and yIFN are potent inhibitors of B1 cell growth. Furthermore, the growth stimulatory effect of IL-1 can be overcome by the addition of these cytokines (data not shown), The corticosteroid 
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dcxi1mcthiiM)nc ;iIw inhihitcd thc growth of RI cclls (Fig 6) . Othcr cytokincs. thc rcccptors for which wcrc undctcctiihlc on I31 CCIIS. such :IS IL-2 and 11-4. fiiilcd 10 itficct RI cell gmwth (Fig 7) . Thc hcmatopoictic grcnvth fistors IL-3. G-CSF. and GM-C3F did not aficct thc growth o f I31 cclls (Fig 7) . In gcncral. t hcrc was cxccllcnt agrccmcnt hctwccn our ability t o dctcct thc cxprcsion of a particular cytokinc rcccptor gcnc. as shown hy thc PCR assay. and our ahility to Table 1 ). PCR products of individual cytokines ware electrophoresed and stained with ethidium bromide as described in Materials and Methods.
and IL-6R gcncs in normal lymphoid and mycloid cclls is rcguIiitccI by I[,-I." Ly IL-6,"" and bvcorticcatcr(~ids."" For instancc. IL-l is not normidly cxprcsscd hy lymphoid and mycloid cclls unlcss induccd hy cxogcnous inducers such as 11.-I or 11.-6."" Hcnvcvcr. in 131 CCIIS IL-I is constitutivclv cxprcssctl (Fig 4A). suwcsting dcmonstrating thc amplification of 11,-1 mcasurcd hy quantitiitivc PCR is prcscntcd in Fig H. A summary of thc cxpcrimcnts pcrformcd on IL-I. IL-IR. and I I A R gcnc cxprcssion is prcscntcd in Fig 9. Thc lcvcl of IL-l mRNA rcmaincd unchangcd in thc prcscncc of cxcxcnously iiddcd IL-1 or IL-6 hut thc comhiniition oft hcsc two cytokincs induccd IL-I cxprcssion (Uoc; wcr control Icvcls: Figs 8 and VA) . Dcxamcthasonc. on thc othcr hand, markcdly dccrcascd 11,-1 mRNA cxprcssion ( F i p H and 9A). as ohscrvcd in norm;il lymphoid ccIIs.u'''rhcsc rcsults indicate that. although thc 11,-1 gcnc is mnstitutivcly cxprcsscd in thc RI lcukcmic cclls. it still maintains wmc of the rcguliltory control clcmcnts of normal hcmatopoictic cclls.
Unstimulatctl RI cclls constitutivcly cxprcsscd high Icv-CIS of IL-IS mRNA amounting to Q . l S r i of total ccll RNA (IS0 ng IL-l mRNA pcr mg total ccll RNA) (Fig YA) . Thc mRNA for 11.-IR is prcscnt in RI cclls at ii much Icnvcr lcvcl (8 nglmg total ccll RNA) and is not affected hy any aimhination of 11.-1 or IL-6 (Fig 9R) . A s rcportcd for normill pcriphcral h l d I3 cclls." IL-I R mRNA is miirkcdly induccd hy dcxamcthiismc in RI cclls (sixfold stimulittion wcr control Icvcls). Thc lcvcls of IL-6R mRNA in unstimulatcd 131 cclls arc unaffcctcd hy 11,-1 and IL-6 hut iirc dccrciascd in thc prcscncc of dcxamcthasonc (Fig K) .
DISCUSSION
Wc dcscrihc hcrc the cstahlishmcnt of a lcukcmic ccll linc with it 4:l I chromcxomal tr;inslcration exhibiting hoth prc-R and mycloid fcilturcs. The growth of this ccll linc is mntrollcd by ;in autocrinc I t~p involving IL-l and its rcccptor and is inhihitcd hy at Icilst four diffcrcnt cytokincs. Thc cstahlishmcnt of this ccll linc allcnvcd us to an;ilyzc thc growth rcgul;ition of hiphcnotypic lcukcmic cclls in vitro.
Thc 4:l I triinslocation oftcn occurs in lcukcmic cclls with an carlv R-ccll prccurwr phcnotypc tcwcthcr with my- The profiles of cytokines and cytokine receptors expressed by B1 cells show both similarities and significant differences to those reported for AML cell^.'^^^^^" Autocrine stimulation of growth by IL-1 has been reported for the majority of AML cases that constitutively express both IL-lp and its r e~e p t o r~,~ as shown here for B1 cells (Figs 4,  8, and 9 ). In addition, TNF and yIFN in some cases inhibited AML cell growth," as observed for B1 cells (Fig  6) . On the other hand, GM-CSF was expressed in the majority of AML samples in combination with either IL-6 or TNF," while neither one of these cytokines is expressed by B1 cells. Little information is available on the cytokine production by ALL cells. However, the growth of ALL cells is stimulated by IL-347.48 and by IL-7.47 In contrast, IL-7 inhibits the growth (Fig 6) of B1 cells while IL-3 has no effect on B1 cell growth (Fig 7) indicating that the growth requirements of these cells are quite different from other ALL or AML cells.
Of all the cytokines tested, only IL-1p is constitutively expressed in B1 cells and is capable of promoting B1 cell proliferation, suggesting that IL-1 is directly responsible for the autocrine regulation of B1 cell growth. In contrast, normal hematopoietic cells do not express IL-1 constitutively but rather produce IL-1 in response to inducers.36, 38,40.41 Taken together, these observations suggest that the constitutive expression of IL-1 and the establishment of IL-1 autocrine growth may be involved in the growth of these leukemic cells. The growth of this leukemic cell line is consistent with the growth characteristics of the initial leukemic cells at relapse. Thus, culture supernatant from the freshly isolated leukemic cells exhibited autocrine growth characteristics, contained hematopoietic growth factor activity, and responded to growth stimulation by IL-1 (data not shown).
Other growth factor receptors commonly associated with leukemic cells such as GM-CSF and IL-6 (AML)>5,'1 IL-3, and IL-7 failed to stimulate B1 cell growth. GM-CSF receptors were not expressed on B1 cells (data not shown) whereas binding of IL-6, IL-7, and TNF to their corresponding receptors, present on Bl cells, inhibited rather than stimulated B1 cell growth (Fig 6) . The unusual expression on B1 cells of the receptors for four growthinhibitory cytokines is quite different from the cytokine expression and responses of conventional AML or ALL cells and may be a characteristic feature of the leukemic subtype with a $11 translocation. Determination of the cytokine profile of other cases with $11 translocations will be required to confirm this hypothesis.
The role of these growth inhibitory interactions in the normal differentiation of hematopoietic cells is still unclear. However, it has been proposed that leukemic cells with a 4;ll chromosomal translocation often originate from an early hematopoietic precursor with biphenotypic differentiation potential.'"I6 It has been proposed that such multipotential hematopoietic precursor cells will express multiple cytokine receptors and may be capable of differentiating into the various lineages in response to specific growth factors." Indeed, differentiation along the monocytic lineage by activation of protein kinase C has been reported in a biphenotypic cell line with a 4;11 transl~cation.'~ The possibility that certain combinations of the cytokine recepFor personal use only. on September 14, 2017. by guest www.bloodjournal.org From tors expressed on B1 cells may induce the differentiation of B1 cells along the myeloid or lymphoid lineages is open for future investigation. On the other hand, the expression of this unusually wide repertoire of four growth inhibitory cytokine receptors on the B1 cells suggests potential treatment strategies for patients with this subtype of leukemia.
It is widely accepted that IL-1 is not expressed constitutively in normal hematopoietic cells but is inducible by a variety of factors affecting cells of myeloid or lymphoid lineage^.^^,^.^' In contrast, the B1 leukemic cells express IL-1 constitutively and IL-1 gene expression could not be induced by either IL-1 or I G 6 alone (Fig 8) . These data suggest that the genetic elements controlling IG1 gene expression may have undergone structural changes during the leukemogenesis process as previously described for other cytokines involved in autocrine growth
